Back to News
May 4, 2026 4:11 PM

Cryoport Posts Revenue Beat In Q1 As Clinical Trial Support Hits All-Time High — 'A Strong Start To 2026'

Cryoport Inc (NASDAQ:CYRX) released financial results for the first quarter of fiscal 2026 Monday after the closing bell. Here's a rundown of the life sciences supply chain provider's results.

CryoPort stock is facing resistance. Why is CYRX stock retreating?

Cryoport Q1 Highlights

Cryoport reported first-quarter revenue of $47.8 million, beating analyst estimates of $44.87 million. The Nashville-based company reported a net loss of 25 cents per share, compared to analyst estimates for a loss of 19 cents.

Total revenue climbed 16% year-over-year, fueled by growth across both primary reporting segments. ...